Management of Supraventricular Tachycardias in Children

Background Supraventricular tachycardias (SVTs) are the most common arrhythmic events in children, with an estimated incidence of 13 per 100,000 per year before the age of 18. Few large patient cohorts have been reported, as most published studies are single-center. Large-scale studies come from medico-administrative databases, which lack the granularity needed for detailed analysis of outcomes according to the therapies used and the type of SVT. Furthermore, although a large proportion of neonatal SVTs do not recur (spontaneous resolution of the accessory pathway), there are limited comparative data on the effectiveness of antiarrhythmic therapies specifically in children after the age of 1 year. Management therefore varies greatly, in part because current guidelines propose different therapeutic options based on low-level evidence. Objectives: * Describe the management of SVTs (antiarrhythmic therapies and catheter ablation) in children in France * Compare the effectiveness of different antiarrhythmic treatments according to age (\<1 year and \>1 year) and type of SVT * Analyze the incidence of adverse events and complications associated with antiarrhythmic treatments and catheter ablation

NCT Number	NCT07291544
Lead Sponsor	Paris Cardiovascular Research Center (Inserm U970)
Conditions	Supraventricular Arrhythmias, Children, Management
Enrollment	1,400 participants
Start Date	2000-01-01
Primary Completion	2025-09-30 (estimated)
Study Completion	2025-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-01-02